MedPath

Medipost Expands in US and Canada; Plans US Phase III of Cartistem

Medipost is expanding its presence in the US and Canada and is planning to initiate a Phase III clinical trial of Cartistem in the US, as part of its growth strategy in the North American market.

Medipost is making significant strides in expanding its operations within the United States and Canada. The company has announced plans to commence a Phase III clinical trial for Cartistem in the US, marking a pivotal step in its strategy to strengthen its foothold in the North American healthcare sector. This move underscores Medipost's commitment to advancing its innovative treatments and therapies to meet the growing demand for regenerative medicine solutions. The expansion and the planned clinical trial are expected to enhance Medipost's capabilities in delivering cutting-edge medical treatments to patients in need, further solidifying its position as a leader in the biotech industry.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

JP Morgan 2025: AbbVie's Strategy with Skyrizi and Rinvoq to Compensate for Humira's Decline

AbbVie is focusing on Skyrizi and Rinvoq to offset the impact of Humira's patent expiration. The company also highlights the success of tavapadon in Parkinson’s disease trials and new partnerships for drug development.

Molecular Partners and Orano Med Expand Partnership for Cancer Therapy Development

Molecular Partners and Orano Med have announced an expanded partnership to develop Targeted Alpha Radio-Therapies for cancer, aiming to enter a first-in-human study for Radio-DARPin MP0712 against DLL3 by 2025 and co-develop a program targeting Mesothelin.

Basilea Announces Portfolio Updates: Cresemba and Zevtera Achieve Key Milestones, Pipeline Progresses

Cresemba's market presence expanded to over 70 countries, achieving USD 533 million in global sales, marking a 20% year-over-year growth and solidifying its position as a leading antifungal.
Zevtera gained FDA approval for SAB, ABSSSI, and CABP, with Innoviva Specialty Therapeutics (IST) announced as the US commercialization partner, targeting a mid-2025 launch.

Axcynsis Therapeutics' AT03-65 Receives FDA IND Clearance for CLDN6-Targeting ADC

Axcynsis Therapeutics received FDA clearance for its IND application for AT03-65, a differentiated CLDN6-targeting antibody-drug conjugate (ADC).
AT03-65 leverages Axcynsis' AxcynDOT™ technology for precise drug delivery to tumors expressing CLDN6, a target in various cancers.

Johnson & Johnson MedTech Temporarily Pauses U.S. Varipulse Cases

Johnson & Johnson MedTech has announced a temporary pause on all U.S. cases using its Varipulse pulsed field ablation (PFA) system starting January 5, as it investigates the root cause of four reported issues.

Hemostemix Reports 83% Success Rate in Phase II Trial, Seeks OTCQB Up-listing

Hemostemix Inc. has announced plans to up-list to the OTCQB Venture Market while reporting significant clinical success with its ACP-01 therapy. Phase II trials showed 83% efficacy in treating peripheral arterial disease, with remarkable improvements in cardiac function and ulcer healing. The company aims to address a market of 236 million PAD patients worldwide.

SeaStar Medical's SCD Shows Multibillion-Dollar Market Potential Across Multiple Indications

SeaStar Medical estimates a $25 to $33 billion U.S. market for its Selective Cytopheretic Device (SCD) across five indications, pending FDA approvals.
The SCD has received FDA Breakthrough Device Designation for adult AKI, hepatorenal syndrome, and cardiorenal syndrome with LVAD, facilitating faster development.

Medipost Expands US Presence, Advances CARTISTEM Phase III Trial for Knee Osteoarthritis

Medipost Inc. is expanding its U.S. presence with key executive appointments to drive its regenerative therapy, CARTISTEM, toward a Phase III clinical trial.
CARTISTEM, an allogeneic human umbilical cord blood-derived mesenchymal stem cell product, is already approved in South Korea for knee osteoarthritis treatment.

OrsoBio Secures $67M for Obesity Drugs, Vor Bio's AML Therapy Shows Promise, and More

OrsoBio, backed by Eli Lilly, raised $67 million to advance its portfolio of weight loss medicines targeting different mechanisms than GLP-1 therapies.
Vor Bio's experimental AML therapy, trem-cel, demonstrated successful engraftment and protection against Mylotarg toxicity in a Phase 1 trial.

J&J Expands Cell Therapy Portfolio with New CAR-T Deals

Johnson & Johnson has secured rights to two experimental cell therapies for blood cancer, aiming to build on its success in CAR-T treatment development. The deal with Cellular Biomedicine Group involves a $245 million upfront payment for access to therapies showing promise in early-phase trials for recurrent diffuse large B cell lymphoma.

Reference News

[1]
Medipost grows US, Canada base; plans US phase III of Cartistem - BioWorld
bioworld.com · Jan 15, 2025

J&J announced a $14.6B acquisition of Intra-Cellular at the J.P. Morgan Healthcare Conference. Abbvie and Simcere signed...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy